Upgrade to SI Premium - Free Trial

BioCryst Pharma (BCRX)

8.17 +0.05 (0.62%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/4/26)

Latest Headlines

RBC Capital Downgrades BioCryst Pharma (BCRX) to Sector Perform September 10, 2026 5:11 AM - StreetInsider TD Cowen Starts BioCryst Pharma (BCRX) at Buy September 8, 2026 10:26 AM - StreetInsider Japan approves BioCryst's Orladeyo for children ages 2 to 12 with HAE August 25, 2026 7:02 AM - StreetInsider BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan August 25, 2026 7:01 AM - Globe NewsWire Form SCHEDULE 13G/A BIOCRYST PHARMACEUTICALS Filed by: RA CAPITAL MANAGEMENT, L.P. August 14, 2026 4:48 PM - SEC Filing Form SCHEDULE 13G BIOCRYST PHARMACEUTICALS Filed by: STATE STREET CORP August 7, 2026 8:56 AM - SEC Filing BioCryst Pharma (BCRX) PT Lowered to $13 at RBC Capital August 6, 2026 6:43 AM - StreetInsider Form S-8 BIOCRYST PHARMACEUTICALS August 5, 2026 4:25 PM - SEC Filing Form 10-Q BIOCRYST PHARMACEUTICALS For: Jun 30 August 5, 2026 4:05 PM - SEC Filing BioCryst Pharma (BCRX) PT Lowered to $20 at Wedbush August 5, 2026 12:40 PM - StreetInsider BioCryst Pharma (BCRX) Tops Q2 EPS by 14c August 5, 2026 7:22 AM - StreetInsider Form 8-K BIOCRYST PHARMACEUTICALS For: Aug 05 August 5, 2026 7:03 AM - SEC Filing BioCryst Reports Second Quarter 2026 Financial Results August 5, 2026 7:00 AM - Globe NewsWire Form 8-K/A BIOCRYST PHARMACEUTICALS For: Jun 25 August 4, 2026 7:01 AM - SEC Filing BioCryst to Report Second Quarter 2026 Financial Results on August 5 July 22, 2026 7:00 AM - Globe NewsWire BioCryst Pharma (BCRX) Reiterated at Market Outperform by Citizens on Orladeyo Potential July 17, 2026 5:10 AM - StreetInsider BioCryst names David Jenkins as chief scientific officer July 15, 2026 7:01 AM - StreetInsider BioCryst Appoints David W. Jenkins as Chief Scientific Officer July 15, 2026 7:00 AM - StreetInsider JPMorgan Resumes BioCryst Pharma (BCRX) at Neutral July 13, 2026 3:15 AM - StreetInsider BioCryst Pharma (BCRX) PT Raised to $14 at RBC Capital July 7, 2026 7:55 AM - StreetInsider BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 2, 2026 7:00 AM - Globe NewsWire BioCryst Pharma (BCRX) PT Raised to $17 at Jefferies June 30, 2026 4:42 AM - StreetInsider Form 8-K BIOCRYST PHARMACEUTICALS For: Jun 25 June 29, 2026 7:07 AM - SEC Filing BioCryst to close Birmingham lab and shift to external R&D model June 29, 2026 7:00 AM - StreetInsider BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility June 29, 2026 7:00 AM - StreetInsider Full Article List